 |
|
An Analysis of Extended Survival in Patients With Amyotrophic Lateral Sclerosis Treated With Riluzole
Marc Riviere, MD;
Vincent Meininger, MD;
Phillipe Zeisser, MD;
Theodore Munsat, MD
Arch Neurol. 1998;55:526-528.
Background In an attempt to better understand and define the progression of amyotrophic lateral sclerosis (ALS), we developed a classification of 5 discrete health states that reflect patients' activities of daily living. These health states were used to determine whether patients with ALS who are treated with riluzole differed from those treated with placebo.
Setting Clinics for patients with ALS.
Design Placebo-controlled trial of riluzole treatment in 959 patients with ALS.
Interventions Treatment with riluzole or placebo.
Main Dependent Measures A Cox model was used to assess whether, from the initial randomization to the end of an 18-month follow-up, there was a difference in the times of transition into subsequent health states between patients treated with riluzole and those treated with placebo.
Results Our analysis showed a significant difference in the time to transit between the riluzole and the placebo groups in less severely affected cases, ie, state 2 and state A (the milder states) of ALS.
Conclusion Patients receiving riluzole remained in the milder health states longer (P<.05).
From Benefit Canada Inc, Montreal, Quebec (Dr Riviere), Hôpital Pitie Salpetriere, Paris, France (Dr Meininger), Rhone-Poulenc Rorer, Antony, France (Dr Zeisser), and Neuromuscular Research Unit, New England Medical Center, Boston, Mass (Dr Munsat).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Outcomes of Physical Therapy, Speech Pathology, and Occupational Therapy for People with Motor Neuron Disease: A Systematic Review.
Morris et al.
Neurorehabil Neural Repair 2006;20:424-434.
ABSTRACT
Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future
Choudry and Cudkowicz
J Clin Pharmacol 2005;45:1334-1344.
ABSTRACT
| FULL TEXT
The management of motor neurone disease
Leigh et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:iv32-47.
FULL TEXT
Management of motor neurone disease
Howard and Orrell
Postgrad. Med. J. 2002;78:736-741.
ABSTRACT
| FULL TEXT
Riluzole for motor neurone disease
Barnett et al.
BMJ 2001;323:573-573.
FULL TEXT
Amyotrophic Lateral Sclerosis
Rowland and Shneider
NEJM 2001;344:1688-1700.
FULL TEXT
Pharmacoeconomics and motor neuron disease
SWASH
J. Neurol. Neurosurg. Psychiatry 2000;68:401-403.
FULL TEXT
Clinical Trials in Motor Neuron Diseases
Miller
J Child Neurol 1999;14:173-179.
ABSTRACT
|
